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A paradoxical increase in circulating Aspergillus antigen was
observed during treatment with caspofungin in a patient with
proven invasive aspergillosis. With the exception of treat-
ment with the echinocandin, no other factors were found
that might explain this clinical observation, which was sup-
ported by experiments done in vitro.
Case report. A 29-year-old man in remission of myelodys-
plastic syndrome was referred to our hospital to receive a T
cell–depleted hematopoietic stem cell transplant (HSCT) from
an unrelated donor. The patient became neutropenic after ad-
ministration of cyclophosphamide, antithymocyte globulin,
and total body irradiation; developed fever 12 days before trans-
plantation; and was treated with meropenem. Blood cultures
yielded Staphylococcus epidermidis, and teicoplanin was added
to the treatment regimen. Plasma samples were tested twice
weekly for circulating galactomannan (Platelia Aspergillus EIA;
BioRad). Although the EIA also detects molecules other than
galactomannan that bear the reactive epitope released by As-
pergillus species, the term “galactomannan” is used in this re-
port. An increase in the galactomannan index from 0.6 to 2.6
was noted 1 day before transplantation. High-resolution CT
(HRCT) also revealed diffuse infiltrates in both lungs, with a
halo sign in the upper left lobe. There were no pulmonary
symptoms, although there was dull percussion of the left upper
lung. These findings met the definition of probable invasive
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aspergillosis, for which our protocol prescribed voriconazole.
However, because the patient had not tolerated treatment with
this azole for possible aspergillosis during an earlier admission
to another hospital, intravenous treatment with caspofungin
(70 mg on the first day, followed by 50 mg once daily) was
started the day of the HSCT. Cyclosporin A treatment was also
started to prevent graft-versus-host-disease, according the stan-
dard protocol. After 3 and 6 days of caspofungin treatment,
the galactomannan index increased to 17.4 and 32.6, respec-
tively; after the sixth day, the index decreased (figure 1). During
this period, there was no evidence of clinical deterioration,
blood cultures yielded only S. epidermidis, and follow-up HRCT
performed 1 week after the start of caspofungin treatment
showed slight progression of the infiltrate in the left upper lobe.
After 2 weeks of caspofungin therapy, kidney and liver function
remained normal, but a second HRCT revealed further pro-
gression of the lesion in the left lung, despite a galactomannan
index of 4.6. The patient developed respiratory insufficiency
and multiorgan failure on day 24 of caspofungin treatment,
coinciding with granulocyte recovery, and was transferred to
the intensive care unit. Antifungal treatment was then changed
to liposomal amphotericin B (200 mg iv once daily), but the
patient’s condition deteriorated. He died 6 days later, 30 days
after the allogeneic HSCT. The galactomannan index at death
was 5.7. Evaluation of tissue of the upper lobe of the left lung
obtained at autopsy revealed invasion by septate hyphae, and
cultures yielded Aspergillus fumigatus. The minimal effective
concentration (MEC) of caspofungin was 0.125 mg/L, and the
MIC of voriconazole was 0.5 mg/L. The MEC was determined
as described previously [1]. The MIC was determined using the
microdilution technique according to the CLSI (formerly known
as the NCCLS) M38-A guidelines [2].
The ability of caspofungin and voriconazole to enhance the
release of galactomannan by the A. fumigatus strain isolated
from tissue was investigated using an in vitro model in which
the release of galactomannan was correlated with fungal bio-
mass. Six growth experiments, each using a single concentration
of caspofungin (MEC, 0.125 mg/L; final concentrations, 0.625
mg/L [ ], 1.25 mg/L [ ], and 2.5 mg/L [205MEC 10MEC
MEC]) and voriconazole (MIC, 0.50 mg/L; final concentra-
tions, 2.5 mg/L [ ], 5 mg/L [ ], and 10 mg/L5MIC 10MIC
[ ]), were conducted. The growth experiments in-20MIC
cluded 6 incubation times (0, 16, 24, 40, 48, and 72 h). A single
growth experiment was conducted without the addition of an
antifungal agent and served as a control. Each culture that
represented a time point consisted of 200 mL of liquid medium
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Figure 1. Galactomannan indices measured in the patient. Day 1 was
the first day of caspofungin treatment and the day of transplantation.
Treatment was changed to liposomal amphotericin B on day 24. HRCT,
high-resolution CT.
Figure 2. In vitro release of galactomannan by the causative Asper-
gillus fumigatus strain versus time, when incubated with 3 concentrations
of caspofungin. Minimum effective concentration, 0.125 mg/L.
(yeast nitrogen base, 100 mmol/L glucose, buffered with 3-[N-
morpholino]propanesulfonic acid [MOPS]; pH, 7.4) that was
inoculated with sufficient A. fumigatus conidia to yield a final
concentration of 104 conidia/mL. The cultures were incubated
at 37C and shaken at 160 rpm. Each drug was added to the
cultures after 16 h of incubation, resulting in the concentrations
described above. At each time point, a culture was filtered (Ø
pore 0.8 mm), and the fungal biomass was determined by freeze-
drying. Galactomannan in the culture filtrate was measured
using the EIA (figure 2). A calibration curve was prepared 6
times with purified galactomannan (0–16 ng/mL; BioRad) to
determine the antigen quantitatively. Reactivity was plotted
against the fungal biomass for each concentration of antifungal
agent. Subsequently, regression lines were calculated during the
logarithmic growth phase, and the EIA reactivity was expressed
as micrograms of galactomannan per milligram of dry weight.
When the A. fumigatus strain was exposed to caspofungin,
the release of antigen in the culture supernatant increased from
8.4 (control value without caspofungin) to 19.2, 56.0, and 110.6
micrograms of galactomannan per milligram of dry weight at
concentrations of , , and , re-5MEC 10MEC 20MEC
spectively. There was no increase detected when the isolate was
exposed to the various concentrations of voriconazole.
Discussion. The concentration of circulating galactoman-
nan has been shown to correspond with clinical outcome in
patients treated with amphotericin B or mold-active antifungal
azoles, with decreasing levels in patients who respond to therapy
and stable or increasing levels in patients for whom therapy
failed [3]. This correlation is less clear for patients treated with
the echinocandin caspofungin. In the case presented, the level
of circulating galactomannan did not correspond with a clinical
response to caspofungin therapy. In fact, a paradoxical increase
in circulating galactomannan was observed with a peak gal-
actomannan index of 32.6. This is significantly higher than the
indices observed among 22 patients with proven and probable
invasive aspergillosis in our hospital who had been treated with
drugs other than caspofungin for proven and probable invasive
aspergillosis ( , ; range 0.3–15.5; ).mean SD 3.4 3.9 Pp .03
Our clinical observation was supported by in vitro experi-
ments in which exposure of the patient’s A. fumigatus strain
to caspofungin, at concentrations comparable to those that can
be achieved during therapy [4, 5], resulted in an increased
release of galactomannan per milligram of biomass. This phe-
nomenon was not observed when the strain was exposed to
voriconazole. In experimental models of invasive aspergillosis
using neutropenic rabbits, rats, and mice, persistently high lev-
els of circulating galactomannan were measured during cas-
pofungin therapy despite clinical improvement [6–8], although
this was not observed among patients with proven invasive
aspergillosis who received salvage therapy with the drug [9].
Drugs that have been shown to cross react with the EIA (e.g.,
piperacillin-tazobactam and amoxicillin-clavulanate) were not
administered to this patient [10]. In addition, the S. epidermidis
isolated from blood cultures has not been shown to cross-react
with the EIA test for galactomannan [11]. The initial increase
in circulating galactomannan did not correspond with clinical
deterioration, nor did it coincide with important changes in
kidney or liver function, leaving treatment with caspofungin
as the most likely explanation for the initial increase in cir-
culating galactomannan. The concomitant initiation of cyclo-
sporin A therapy could have had an effect on the release of
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galactomannan, because the drug is known to increase exposure
to caspofungin by up to 35% [12]. Furthermore, this drug
exhibits antifungal activity against A. fumigatus and appears
synergistic in vitro when combined with caspofungin [13, 14].
An initial increase in circulating galactomannan might be
expected in patients treated with this class of antifungal agents
as a result of the mechanism of action of the drug. In a rabbit
model of invasive aspergillosis, exposure to caspofungin re-
sulted in fragmentation of Aspergillus hyphae in the tissue and
in an increase in the number of hyphal tips [6]. Some galac-
tomannan is released at the hyphal tips, which may have re-
sulted in the increased release of galactomannan in conjunction
with degradation of the cell wall. Because some galactoman-
nan is covalently bound to (1,3)-b-d-glucan in the fungal cell
wall [15], exposure to caspofungin would result in a reduced
amount of (1,3)-b-d-glucan molecules in the cell wall and,
therefore, an increased release of galactomannan.
Amphotericin B and the azoles are cell membrane–active
agents and have been shown to cause morphological alterations
to the fungal cell wall [16, 17]. Persistently higher levels of
circulating galactomannan were observed in mice with invasive
aspergillosis that were given monotherapy with caspofungin
and not in those treated with a combination of the echino-
candin and amphotericin B [8]. Therefore, preexposure of the
fungus to azoles or amphotericin B could have an impact on
the release of galactomannan during subsequent caspofungin
therapy. This might explain the lack of a paradoxical increase
in galactomannan among patients given caspofungin for salvage
therapy because they had already been exposed to other anti-
fungal agents [9].
In conclusion, this is, to our knowledge, the first clinical
report to describe a paradoxical increase in circulating galac-
tomannan after caspofungin treatment for proven invasive as-
pergillosis. Further research is warranted to determine the fre-
quency and significance of this clinical observation. In any
event, this case shows that results of galactomannan monitoring
among patients treated with caspofungin therapy should be
interpreted with caution.
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